Asian Pacific Journal of Cancer Prevention

  • 제16권2호
  • /
  • Pages.823-829
  • /
  • 2015
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α Expression in Invasive Ductal Breast Cancer Patients and Correlations with Prognosis

  • Yan, Jian (Department of General Surgery, The Third Affiliated Hospital of Southern Medical University) ;
  • Liu, Xiao-Long (Department of General Surgery, The Third Affiliated Hospital of Southern Medical University) ;
  • Han, Lu-Zhe (Department of General Surgery, The Third Affiliated Hospital of Southern Medical University) ;
  • Xiao, Gang (Department of General Surgery, The Third Affiliated Hospital of Southern Medical University) ;
  • Li, Ning-Lei (Department of General Surgery, The Third Affiliated Hospital of Southern Medical University) ;
  • Deng, Yi-Nan (Guangdong Provincial Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University) ;
  • Yin, Liang-Chun (Department of General Surgery, The Third Affiliated Hospital of Southern Medical University) ;
  • Ling, Li-Juan (Department of General Surgery, The Third Affiliated Hospital of Southern Medical University) ;
  • Yu, Xiao-Yuan (Department of General Surgery, The Third Affiliated Hospital of Southern Medical University) ;
  • Tan, Can-Liang (Department of General Surgery, The Third Affiliated Hospital of Southern Medical University) ;
  • Huang, Xiao-Ping (Department of General Surgery, The Third Affiliated Hospital of Southern Medical University) ;
  • Liu, Li-Xin (Department of General Surgery, The Third Affiliated Hospital of Southern Medical University)
  • 발행 : 2015.02.25
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The aim of the present study was to investigate the expression of the transcription factor Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-${\alpha}$ in the tumor tissue of patients with invasive ductal carcinoma(IDC); in addition, we examined correlations between these markers. Two hundred and sixteen IDC patients, who were not previously been treated with chemo- or radiotherapy, were included in the study. All tumors were grade I-III. Expression of molecular markers was determined by immunohistochemical analysis on paraffin-embedded tissue sections. Follow-up data were collected for 3 months to 10 years and analyzed for tumor recurrence, survival time, and prognostic risk factors. We determined Ki-67 expression correlates with the expression of ER, PR, HER-2, EGFR, and TOP-${\alpha}$, as well as lymph node involvement, high tumor grade, lymphovascular invasion, high tumor stage, and high TNM stage in IDC. Positive Ki-67 expression was a risk factor for rapid tumor recurrence and may help tumor progression, leading to poor prognosis in IDC. Ki-67 was directly correlated with EGFR, TOP II-${\alpha}$, lymph node involvement, high tumor grade, lymphovascular invasion, high tumor stage, and high TNM stage in the hormone receptor subtypes of breast cancer. In triple negative breast cancer, Ki-67 correlated with TOP II-${\alpha}$. Expression of Ki-67 correlated with that of ER, PR, HER-2, EGFR, TOP II-${\alpha}$, and p21. In addition, the biomarker Ki-67 has a role as a prognostic factor and indicates a poor prognosis in IDC.

키워드

참고문헌

  1. Agboola AO, Banjo AA, Anunobi CC, et al (2011). Evaluating TIMP-1, Ki67, and HER2 as markers for non-sentinel node metastases in breast cancer patients with micrometastases to the sentinel node. APMIS, 119, 844-52. https://doi.org/10.1111/j.1600-0463.2011.02768.x
  2. Agboola AO1, Banjo AA, Anunobi CC, et al (2013). Cell proliferation (KI-67) expression is associated with poorer prognosis in nigerian compared to British breast cancer women. ISRN Oncol, 11, 675-85.
  3. Arshad H, Ahmad Z, Hasan SH (2010). Gliomas: correlation of histologic grade, Ki67 and p53 expression with patient survival. Asian Pac J Cancer Prev, 11, 1637-40.
  4. Ashrafi M, Bathaie SZ, Abroun S (2012). High expression of Cyclin D1 and p21 in N-Nitroso-N-Methylurea-Induced breast cancer in wistar albino female rats. Cell J, 14, 193-202.
  5. Bartek J, Lukas J (2007). DNA damage checkpoints: from initiation torecovery or adaptation. Curr Opin Cell Biol, 19, 238-45. https://doi.org/10.1016/j.ceb.2007.02.009
  6. Bjerre C, Knoop A, Bjerre K, et al (2013). Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer. Acta Oncol, 52, 82-90. https://doi.org/10.3109/0284186X.2012.734922
  7. Cancer in Ukraine, 2008-2009 (2010): Bulletin of national cancer registry of Ukraine No.11. Kyiv. 111 p.
  8. Carnero A, Beach DH (2004). Absence of p21WAF1 cooperates withc-myc in bypassing Ras-induced senescence and enhances oncogeniccooperation. Oncogene, 23, 6006-11. https://doi.org/10.1038/sj.onc.1207839
  9. Chan A, Conte PF, Petruzelka L, et al (2013). Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer. Anticancer Res, 33, 2657-64.
  10. Chan MS, Wang L, Felizola SJ, et al (2012). Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients--an immunohistochemical study of Cd8+ and Foxp3+ using double immunostaining with correlation to the pathobiological response of the patients. Int J Biol Markers. 27, 295-304. https://doi.org/10.5301/JBM.2012.10439
  11. Chen Y, Wang J, Wang X, et al (2013). STAT3, a poor survival predicator, is associated with lymph node metastasis from breast cancer. J Breast Cancer, 16, 40-9. https://doi.org/10.4048/jbc.2013.16.1.40
  12. Dede DS, Gumuskaya B, Guler G, et al (2013). Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel. J BUON, 18, 57-63.
  13. Eom M, Lkhagvadorj S, Oh SS, et al (2013). ROS1 expression in invasive ductal carcinoma of the breast related to proliferation activity. Yonsei Med, 54, 650-7. https://doi.org/10.3349/ymj.2013.54.3.650
  14. Ferguson NL, Bell J, Heidel R, et al (2013). Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women. Breast J, 19, 22-30. https://doi.org/10.1111/tbj.12059
  15. Galea GL, Meakin LB, Sugiyama T, et al (2103). Estrogen receptor $\alpha$ mediates proliferation of osteoblastic cells stimulated by estrogen and mechanical strain, but their acute down-regulation of the Wnt antagonist Sost is mediated by estrogen receptor $\beta$. J Biol Chem, 288, 9035-48 https://doi.org/10.1074/jbc.M112.405456
  16. Hanahan D (2000).Weinberg RA.The hallmarks of cancer. Cell, 100, 57-70. https://doi.org/10.1016/S0092-8674(00)81683-9
  17. Hendrayani SF, Al-Khalaf HH, Aboussekhra A(2013). Curcumin triggers p16-dependent senescence in active breast cancerassociated fibroblasts and suppresses their paracrine procarcinogenic effects. Neoplasia, 15, 631-40. https://doi.org/10.1593/neo.13478
  18. Ibrahim T, Farolfi A, Scarpi E, et al (2013). Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact. Oncology, 84, 150-7. https://doi.org/10.1159/000345795
  19. Inwald EC, Klinkhammer-Schalke M, Hofstadter F, et al (2013). Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat, 139, 539-52. https://doi.org/10.1007/s10549-013-2560-8
  20. Kamineni A, Anderson ML, White E, et al (2013). Body mass index, tumor characteristics, and prognosis following diagnosis of early-stage breast cancer in a mammographically screened population. Cancer Causes Control, 24, 305-12. https://doi.org/10.1007/s10552-012-0115-7
  21. Kanavaros P, Bai M, Stefanaki K, et al (2001). Immunohistochemical expression of the p53, mdm2, p21/Waf-1, Rb, p16, Ki67, cyclin D1, cyclin A and cyclin B1 proteins and apoptotic index in T-cell lymphomas. Histol Histopathol, 16, 377-86.
  22. Klijin JGM (1991). Clinical parameters and symptoms for the progression to endocrine independence of breast cancer. In: mechanisms of progression to hormone-independent growth of breast and prostatic cancer. Carnfoth: The Parthenon Publishing Group, 11-9.
  23. Lemieux J, Diorio C, Cote MA, et al (2013). Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab. Anticancer Res, 33, 2569-76.
  24. Loehberg CR, Almstedt K, Jud SM, et al (2013). Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis. Breast Cancer Res Treat. 138, 899-908. https://doi.org/10.1007/s10549-013-2460-y
  25. Martin-Caballero J, Flores JM, Garcia-Palencia P, et al (2001). Tumorsusceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res, 61, 6234-8.
  26. Meattini I1, Livi L, Saieva C, et al (2013). Prognostic role of human epidermal growth factor receptor 2 status in premenopausal early breast cancer treated with adjuvant tamoxifen. Clin Breast Cancer, 14, 1526-33.
  27. Midura-Nowaczek K, Purwin M, Markowska A, et al (2013). Effect of short peptides containing lysine and epsilonaminocaproic acid on fibrinolytic activity of plasmin and topoisomerase II action on supercoiled DNA. Acta Pol Pharm, 70, 431-4.
  28. Mrklic I, Capkun V, Pogorelic Z, et al (2013). Prognostic value of Ki-67 proliferating index in triple negative breast carcinomas. Pathol Res Pract, 209, 296-301. https://doi.org/10.1016/j.prp.2013.02.012
  29. Mrklic I, Pogorelic Z, Capkun V, Tomic S (2013). Expression of topoisomerase II-$\alpha$ in triple negative breast cancer.Appl Immunohistochem Mol Morphol, 22, 132-41.
  30. Pathmanathan N, Balleine RL(2013). Ki67 and proliferation in breast cancer. J Clin Pathol, 66, 512-6. https://doi.org/10.1136/jclinpath-2012-201085
  31. Perissinotti AJ, Lee Pierce M, Pace MB,et al(2013). The role of trastuzumab in the management of salivary ductal carcinomas. Anticancer Res, 33, 2587-91.
  32. Poole AJ, Heap D, Carroll RE, Tyner AL(2004). Tumor suppressor functions forthe CDK inhibitor p21 in the mouse colon. Oncogene, 23, 8128-34. https://doi.org/10.1038/sj.onc.1207994
  33. Ryu DW, Lee CH(2012). Outcome of triple-negative breast cancer in patients with or without markers regulating cell cycle and cell death. J Korean Surg Soc, 83, 187-95. https://doi.org/10.4174/jkss.2012.83.4.187
  34. Salehi F, Agur A, Scheithauer BW, et al (2009).Ki-67 in pituitaryneoplasms: a review--part I. Neurosurgery, 65, 429-37. https://doi.org/10.1227/01.NEU.0000349930.66434.82
  35. Sherr CJ, Roberts JM(1999). CDK inhibitors: positive and negative regulatorsof G1-phase progression. Genes Dev, 13, 1501-2. https://doi.org/10.1101/gad.13.12.1501
  36. Sorbye SW1, Kilvaer TK, Valkov A, et al (2012). Prognostic Impact of Jab1, p16, p21, p62, Ki67 and Skp2 in Soft TissueSarcomas. PLoS ONE, 7, 47068. https://doi.org/10.1371/journal.pone.0047068
  37. Synnestvedt M, Borgen E, Russnes HG, et al (2013). Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy. Acta Oncol, 52, 91-101. https://doi.org/10.3109/0284186X.2012.713508
  38. Szelachowska J, Dziegiel P, Tarkowski R, et al (2012). Therapeutic radiation induces different changes in expression profiles of metallothionein (MT) mRNA, MT protein, Ki 67 and minichromosome maintenance protein 3 in human rectal adenocarcinoma. Anticancer Res, 32, 5291-7.
  39. Tarhan MO, Gonel A, Kucukzeybek Y, et al (2013). Prognostic significance of circulating tumor cells and serum CA15-3 levels in metastatic breast cancer, single center experience, preliminary results. Asian Pac J Cancer Prev. 14, 1725-9. https://doi.org/10.7314/APJCP.2013.14.3.1725
  40. Tawfik K, Kimler BF, Davis MK, et al (2013). Ki-67 expression in axillary lymph node metastases in breast cancer is prognostically significant. Hum Pathol, 44, 39-46. https://doi.org/10.1016/j.humpath.2012.05.007
  41. Thor AD, Liu S, Moore DH, et al (2000). p (21WAF1/CIP1) expression in breast cancers: associations with p53 and outcome. Breast Cancer Res Treat, 61, 33-43. https://doi.org/10.1023/A:1006455526894
  42. Xiong Y, Hannon GJ, Zhang H, et al (1993). p21 is a universal inhibitor ofcyclin kinases. Nature, 366, 701-4. https://doi.org/10.1038/366701a0
  43. Yang W, Velcich A, Lozonschi I, et al (2005). Inactivation of p21WAF1/cip1 enhances intestinal tumor formation in Muc2-/- mice. Am J Pathol, 166, 1239-46. https://doi.org/10.1016/S0002-9440(10)62342-5

피인용 문헌

  1. Clinicopathological implications of Tiam1 overexpression in invasive ductal carcinoma of the breast vol.16, pp.1, 2016, https://doi.org/10.1186/s12885-016-2724-0
  2. Relationship between erb-B2 mRNA Expression in Blood and Tissue of Invasive Ductal Carcinoma Breast Cancer Patients and Clinicopathological Characteristics of the Tumors vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.249
  3. Relationship between HER2 Proto-oncogene Status and Prognostic Factors of Breast Cancer in the West of Iran vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.295
  4. p53, Cyclin D1, p21 (WAF1) and Ki-67 (MIB1) Expression at Invasive Tumour Fronts of Oral Squamous Cell Carcinomas and Development of Local Recurrence vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.1243
  5. 厚朴酚缓解热应激诱导的小肠上皮细胞损伤及其分子机制 vol.17, pp.6, 2016, https://doi.org/10.1631/jzus.B1500261
  6. ATP citrate lyase is increased in human breast cancer, depletion of which promotes apoptosis vol.39, pp.4, 2017, https://doi.org/10.1177/1010428317698338
  7. Prediction model of lymphovascular invasion based on clinicopathological factors in Chinese patients with invasive breast cancer vol.97, pp.43, 2018, https://doi.org/10.1097/MD.0000000000012973